MMSI Earnings Date: Feb 24, 2027 (Estimated) — Merit Medical Systems, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is MMSI's next earnings date?
Merit Medical Systems, Inc. (MMSI) is expected to report Q4 2026 earnings on Wednesday, February 24, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.11 on revenue of $424.7M.
How did MMSI do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Merit Medical Systems, Inc. posted EPS of $1.12 versus the $1.04 estimate, a beat of 7.7%. Revenue was $416.2M against a $410.6M estimate.
How much does MMSI stock move after earnings?
MMSI beat EPS estimates in 8 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.5% (up or down) in the day after earnings.
About Merit Medical Systems, Inc.
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
🤖 AI Earnings Analysis
Merit’s Solo Pace acquisition expands its cardiac therapies platform, while raised 2026 guidance reinforces a strong quarter: organic constant-currency revenue grew 9% to $416 million and EPS beat estimates by $0.08.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 1.04 | 1.12 | +7.69% | $416.2M | ✅ Beat | — | — | — |
| 2026-07-30 | Q2 2026 | 0.94 | 1.19 | +26.60% | $418.8M | ✅ Beat | +1.99% | +5.21% | +8.57% |
| 2026-04-30 | Q1 2026 | 0.81 | 0.94 | +16.05% | $381.9M | ✅ Beat | -9.05% | -8.58% | -8.99% |
| 2026-02-24 | Q4 2025 | 0.91 | 1.04 | +14.29% | $393.9M | ✅ Beat | -3.88% | -9.20% | -17.37% |
| 2025-10-30 | Q3 2025 | 0.79 | 0.92 | +16.46% | $384.2M | ✅ Beat | +5.42% | +4.18% | +4.03% |
| 2025-07-30 | Q2 2025 | 0.82 | 1.01 | +23.17% | $382.5M | ✅ Beat | +2.29% | +0.71% | +8.55% |
| 2025-04-24 | Q1 2025 | 0.75 | 0.86 | +14.67% | $355.4M | ✅ Beat | -0.06% | -1.55% | +0.75% |
| 2025-02-25 | Q4 2024 | 0.83 | 0.93 | +12.05% | $355.2M | ✅ Beat | -1.55% | -0.14% | +1.64% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $142.5M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Therapeutic | 98.6% | $140.5M | — | — | — | — | — |
| Product and Service, Other | 1.4% | $2.0M | — | — | — | — | — |
By region
Q3 FY26 · $416.2M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 61.5% | $255.9M | — | $213.6M | $227.1M | — | — |
| Non-US | 38.5% | $160.3M | +4.4% | $141.8M | $155.4M | $153.6M | $155.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.